AALRX | VIVIX | AALRX / VIVIX | |
Total Expense Ratio | 0.62 | 0.04 | 1,550% |
Annual Report Gross Expense Ratio | 0.62 | 0.04 | 1,550% |
Fund Existence | 9 years | 27 years | - |
Gain YTD | 9.388 | 7.866 | 119% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 0 | 5000000 | - |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 3.41B | 203B | 2% |
Annual Yield % from dividends | 1.61 | 2.11 | 76% |
Returns for 1 year | 0.31 | 7.74 | 4% |
Returns for 3 years | 18.90 | 36.61 | 52% |
Returns for 5 years | 29.26 | 70.16 | 42% |
Returns for 10 years | N/A | 131.61 | - |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
LYFCX | 12.99 | 0.21 | +1.64% |
AlphaCentric Life Sciences & Hlthcare C | |||
JEMWX | 37.58 | 0.41 | +1.10% |
JPMorgan Emerging Markets Equity R6 | |||
CLARX | 8.19 | 0.06 | +0.74% |
NYLI CBRE Real Estate Class A | |||
IMIDX | 23.31 | 0.16 | +0.69% |
Congress Mid Cap Growth Institutional | |||
MXYKX | 5.32 | -0.14 | -2.56% |
Empower T. Rowe Price Mid Cp Gr Instl |